Search results
Showing 1 to 15 of 160 results for prostate cancer
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
All NICE products on prostate cancer. Includes any guidance, advice and quality standards.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Evidence-based recommendations on docetaxel for treating hormone-refractory metastatic prostate cancer in adults.
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.